CD80 and neoplasm: Recently, Lamberti et al. (2019) demonstrated that methyl-aminolevulinic acid (Me-ALA)-PDT could induce anti-tumor immune responses [132] This ICD was mediated through a type I-interferon (IFN)-1-dependent pathway, which is able to activate DCs expressing co-stimulatory ligands (CD80, MHC-II), which eventually facilitated the priming of immune effector cells and tumor destruction in an antigen-dependent manner [132].